poisar

Stocks · News reference

Medpace Announces Webinar on Glomerular Disease Clinical Trials

Fiscal.ai

Medpace is hosting a webinar focused on integrated, cross-functional strategies for managing glomerular disease clinical trials.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks Investment ResearchNa

    RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs

    ResMed (RMD) delivered solid first-quarter fiscal 2027 results with adjusted EPS of $2.91, up 14% year-over-year and beating consensus by 9%. Revenues grew 6% to $1.41 billion, driven by sustained demand for sleep devices and masks. Gross margins expanded 50 basis points to 62.5% from productivity gains. However, the company faced headwinds from discontinued Astral life-support device sales and the MatrixCare divestiture. RMD maintained its fiscal 2027 guidance for 5-7% core constant-currency revenue growth and $12.00-$12.25 adjusted EPS.